Schulhoff & Co’s Fate Therapeutics FATE Stock Holding History

Schulhoff & Co’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$270K	Hold	100,000	–	–	0.11%	123
2026 Q1	$120K	Buy	+100,000	New	+$122K	0.05%	132

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Schulhoff & Co's FATE Position: Q2 2026 in Review

Schulhoff & Co held its Fate Therapeutics (FATE) position steady in Q2 2026 at 100,000 shares worth $270K. The position accounts for 0.11% of the portfolio, ranked #123.

Schulhoff & Co first reported a position in FATE in Q1 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Schulhoff & Co held 100,000 shares of Fate Therapeutics worth $270K as of Q2 2026.
Schulhoff & Co left its Fate Therapeutics share count unchanged in Q2 2026.
Fate Therapeutics made up 0.11% of Schulhoff & Co's portfolio in Q2 2026, its #123 holding.
Schulhoff & Co first reported a position in Fate Therapeutics in Q1 2026 and has held it in 2 quarters since.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Schulhoff & Co's 13F filing for Q2 2026, filed 13 Aug 2026.